IMO the issue at the moment isn't just sales volumes, but the direct costs associated with ramping up sales eg staffing costs. This needs to be significantly reduced, and thus profits improved.
The other issue for me is the lack of direction, The company along with it's investors doesn't exactly know where it's heading in the next 12 months. Eg Will we run another Phase 3 for the FDA, and concentrate on cutting expenses associated with Bronchitol in the EU? Or will the Bronchiectasis results mean we file for a label adjustment with the EMA, and concentrate all our resources in raising awareness for Bronchitol in the EU?
The $1 you talk of is all but a dream for me at the moment.
PXS Price at posting:
28.5¢ Sentiment: None Disclosure: Held
